This suggests successful differentiation of acute iTTP patients from patients with alternative TMAs such as HUS, which could thereby largely benefit the diagnosis of iTTP patients that present ADAMTS13 activity ranging from 10 to 20%. This evidence concerns the gene ADAMTS13 and hemolytic-uremic syndrome.